Pharmaceutical company Novartis is working on a pill that could serve as a comprehensive treatment for all varieties of coronavirus, and not just COVID-19, according to Reuters.
A universal remedy: After playing a collaborative role in the vaccine manufacturing process in the early stages of the COVID-19 pandemic, Novartis signed a deal with Molecular Partners last year to execute two protein-based treatments for COVID-19, and information from studies of one of those treatments is expected in January.
A shift toward reasonable returns: Initially, many pharmaceutical companies sold COVID-19 treatments at cost. But with the early days of the pandemic in the rearview mirror, drugmakers are looking to return to a more profitable model of production to create sustainable economic benefit and continue investing in drug development and retail.
A team effort: Novartis CEO Vas Narasimhan noted the importance of teamwork and cooperation among pharmaceutical companies in creating vaccines and other products designed to reduce the impact of the COVID-19 pandemic.
- “I think we as a sector have collaborated extremely well to ultimately be the industry that enabled this pandemic over time to eventually be under control,” said Narasimhan.